Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $3.9452W HIGH $9.10
Volume
7.83 K
Value Traded
40.99 K
Short % Float
0.48%
-0.86%Week
-8.91%1 Month
-23.33%3 Month
+1.1%6 Month
-99.8%5 Year
-99.83%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
52.22 M
EPS (TTM)
-4.82
P/E Ratio
-
Ent. Value
-83.94 M
Total Shares
11.35 M
Float Shares
7.26 M
Insiders
36.07%
Institutions
34.10%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
IMA Catalyst Timeline
Dated clinical, regulatory and corporate events for ImageneBio, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for ImageneBio, Inc.
108Total events
8Upcoming
19Tier-1 (high impact)
2021 to 2028Coverage
Upcoming catalysts 2
Event history 50
●Equity OfferingCorporate
Inducement awards of 90,775 RSUs and 32,725 NSOs granted to three new employees
▲Safety Data UpdateolevaprubartClinical Data
No cases of Kaposi sarcoma observed as of July 31, 2026
▲DSMB ReviewolevaprubartTrial
IDMC recommended study proceed with no changes
atopic dermatitissource ↗
◆Oral PresentationIMG-007Presentation
Oral presentation of preclinical data at SID Meeting
inflammatory and autoimmune diseasesource ↗
▼Equity OfferingCorporate
ImageneBio announces $30 million private placement led by Coastlands Capital
◆Oral PresentationPresentation
Management to participate in fireside chat at Leerink Global Healthcare Conference
●Protocol AmendmentIMG-007Trial
Protocol amendment for ongoing Phase 2b ADAPTIVE study of IMG-007 in atopic dermatitis announced
atopic dermatitissource ↗
◆Oral PresentationIMG-007Presentation
Oral presentation of alopecia areata data including biomarkers from Phase 1b/2a study at ISDS
alopecia areatasource ↗
▲Trial CompletionIMG-007Trial
Phase 2a clinical trial completed in atopic dermatitis
atopic dermatitissource ↗
▲First Patient DosedIMG-007Trial
First patients treated in global Phase 2B study in atopic dermatitis
atopic dermatitissource ↗
▲Topline ReadoutIMG-007Clinical Data
Phase 2a trial in atopic dermatitis completed
atopic dermatitissource ↗
▲First Patient DosedIMG-007Trial
First patient dosed in Phase 2b ADAPTIVE trial of IMG-007 for moderate-to-severe atopic dermatitis
moderate-to-severe atopic dermatitissource ↗
▲Enrollment CompleteIMG-007Trial
ADAPTIVE trial began enrolling in mid-2025
moderate-to-severe atopic dermatitissource ↗
◆Trial InitiationIMG-007Trial
Phase 2b clinical trial in atopic dermatitis expected to begin
atopic dermatitissource ↗
◆AcquisitionCorporate
Ikena Oncology and Inmagene Biopharmaceuticals enter into definitive merger agreement
●Quarterly UpdateCorporate
Ended first quarter with $157.3 million; exploring strategic options
◆Timing GuidancePresentation
Clinical update for IK-930 and IK-595 expected in second half of 2024
◆Topline ReadoutIK-930DiscontinuedClinical Data
Additional monotherapy data expected in 2H 2024
cancersource ↗
◆Timing GuidanceIK-930DiscontinuedPresentation
Additional IK-930 clinical data update planned for second half of 2024
solid tumorssource ↗
▲First Patient DosedIK-930DiscontinuedTrial
IK-930 optimized formulation now in the clinic
cancersource ↗
▲First Patient DosedIK-595Trial
IK-595 first cohort treated and cleared safety evaluation window
cancersource ↗
Past FDA Catalysts and PDUFA Decisions
How IMA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-30 | Olevaprubart (IMG-007) | Phase 1b/2a data readout | Phase 1b/2a |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D37 / 100
Pipeline Score
$124M
Pipeline Value
Undervalued
Valuation Signal
3
Drugs Scored
7.9x
rNPV / MCap
Top 48%
Micro Cap(rank 316 of 658)
Percentile Rank
ImageneBio, Inc. faces pipeline headwinds (37/100), with $494M risk-adjusted pipeline value, led by IMG-007 in Atopic Dermatitis (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| IMG-007 Small moleculeNCT07734415 | Atopic Dermatitis | Phase 2 | ENROLLING BY_INVITATION | 805 | Mar 1, 2028 |
Clinical Trial Results
Readouts, endpoints and source filings for every IMA program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| IK-930 | epithelioid hemangioendothelioma | Phase 1 | 2023-11-09 | patients treated: 26; tumor shrinkage: encouraging signs; treatment related proteinuria: 3 out of 26 patients; proteinuria grade: grade 1-2Read More | Ikena Oncology Shares Initial Positive and Differentiated Dose Escalation Data from IK-930 Phase I Trial and Reports Third Quarter 2023 Financial Results Favorable safety profile in dose escalation shown to date; selectiRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Yarema KristinDirector, Officer (Chief Executive Officer) | Option | 38,376 123,776 held | $0.00 | 07/25/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in IMA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| BVF INC/IL | 0.2 % | 6.55 M | 1.11 M |
IMA Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How IMA ranks across every disease it competes in
Competitive Position is a premium feature
See how IMA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialIMA News
IMA▲ +0.4%today
ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ImageneBio, Inc. announced the granting of inducement awards to three new employees, consisting of 90,775 restricted stock units and 32,725 non-qualified stock options. These awards are part of the company's strategy to attract talent under Nasdaq Listing Rule 5635(c)(4). Additionally, Imagene is advancing its clinical trials for its lead therapeutic candidate, olevaprubart, targeting immunological diseases.
Read more →IMAImageneBio to Participate in H.C. Wainwright 28th Annual Global Investment Conference in New York
ImageneBio, Inc. announced that CEO Kristin Yarema will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026. The company is engaged in developing therapeutics for immunological diseases and is currently conducting a Phase 2b clinical trial for its drug, olevaprubart, in atopic dermatitis. This event highlights ImageneBio's ongoing commitment to advancing its clinical programs.
Read more →IMAImageneBio Reports Second Quarter 2026 Financial Results
ImageneBio reported its Q2 2026 financial results, highlighting progress in the Phase 2b ADAPTIVE trial of its drug Olevaprubart for atopic dermatitis. The company has opened a long-term extension study and plans to initiate a Phase 2 trial for alopecia areata. Despite a net loss of $10.2 million, Imagene maintains a robust cash position of $136.2 million, sufficient to fund operations into 2028.
Read more →IMAImageneBio Appoints Matt Robbins as General Counsel
ImageneBio has appointed Matt Robbins as General Counsel, effective July 7, 2026. Robbins, an experienced attorney in life sciences, will oversee legal and compliance functions as the company advances its lead candidate, IMG-007. ImageneBio is excited about its growth phase and upcoming clinical milestones in treating atopic dermatitis and alopecia areata.
Read more →IMAImageneBio to Participate in 2026 Jefferies Global Healthcare Conference in New York
ImageneBio, Inc. announced its participation in the Jefferies Global Healthcare Conference on June 4, 2026. CEO Kristin Yarema will present at the event, which will also include one-on-one meetings with management. The company is focused on developing therapies for immunological and autoimmune diseases, with ongoing clinical trials for its product IMG-007.
Read more →IMAImageneBio Reports First Quarter 2026 Financial Results and Provides IMG-007 Program Update
ImageneBio reported its Q1 2026 financial results and provided updates on its lead program, IMG-007, which is advancing into a Phase 2 clinical trial for alopecia areata. The company secured $30 million in financing, extending its cash runway into early 2028. IMG-007 is notable for its non-T cell-depleting mechanism and is currently being evaluated in a Phase 2b trial for atopic dermatitis with topline data expected in late 2027.
Read more →IMA▲ +23.4%on this news
ImageneBio Announces $30 Million Private Placement
ImageneBio has announced a $30 million private placement with institutional investors to fund the development of its drug IMG-007 for alopecia areata and atopic dermatitis. The company is optimistic about the progress of its Phase 2b ADAPTIVE trial and the potential of IMG-007 as a disease-modifying treatment. The placement involves pre-funded warrants and is led by Coastlands Capital.
Read more →IMAImageneBio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update
ImageneBio, Inc. reported its financial results for Q4 and full year 2025, highlighting the promising clinical progress of its lead candidate, IMG-007, an OX40 antagonist. The company has observed no significant tolerability issues, differentiating it from its competitors. With a robust financial position, bolstered by recent funding and a merger, it plans to advance its Phase 2b ADAPTIVE trial in atopic dermatitis, while remaining aware of competition and potential safety concerns in the field. An upcoming presentation at the SID Meeting will showcase additional preclinical data on IMG-007's innovative profile.
Read more →IMAImageneBio to Participate in Leerink Global Healthcare Conference
ImageneBio, Inc. will participate in the 2026 Leerink Global Healthcare Conference from March 8-11 in Miami, Florida. The company will engage in a fireside chat and hold one-on-one meetings to discuss its clinical-stage programs, particularly IMG-007, which is in Phase 2b trials for atopic dermatitis. This involvement highlights the company's commitment to advancing its therapeutic developments.
Read more →IMAImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer
ImageneBio has appointed Dr. Ben Porter-Brown as Chief Medical Officer to lead its clinical organization and oversee the Phase 2b ADAPTIVE trial for atopic dermatitis. With over 20 years of experience in autoimmune and inflammatory diseases, Dr. Porter-Brown aims to enhance the company's clinical capabilities and expand its trial sites internationally. His expertise in OX40 signaling inhibitors is expected to significantly benefit the development of Imagene's drug IMG-007.
Read more →IMAImageneBio Corporate Overview Fourth Quarter 2025 Disclaimer and forward-looking statements This investor presentation and any accompanying oral commentary have been prepared by ImageneBio, Inc. (the Company) for informa
ImageneBio, Inc. presented an overview of its corporate status and future prospects, highlighting its immunology innovations, particularly IMG-007, aimed at treating atopic dermatitis. The presentation emphasized the current unmet needs in the atopic dermatitis market, where existing treatments fall short for a significant portion of patients. ImageneBio has a well-established funding runway anticipated to extend until the end of 2027, supporting their ongoing Phase 2b clinical studies. However, risks surrounding the clinical development process and dependency on external partners were also noted.
Read more →IMAImageneBio Reports Third Quarter 2025 Financial Results and Provides IMG-007 Program Update Following Closing of Reverse Merger, Concurrent Financing, and Strengthening of Management Team $142.6 million cash and cash equ
ImageneBio reported its third quarter 2025 financial results, revealing a cash balance of $142.6 million following a reverse merger and concurrent financing. The company provided an update on the ongoing Phase 2b ADAPTIVE study of its anti-OX40 monoclonal antibody, IMG-007, focusing on atopic dermatitis, highlighting strong patient enrollment and planned protocol amendments to optimize the trial. Leadership changes and upcoming data presentations at a key summit further indicate an active progression in their clinical programs. However, the firm also noted a substantial net loss and ongoing risks linked to clinical and regulatory developments.
Read more →IMAI MAGENE B IO , I NC . 2025 E QUITY I NDUCEMENT P LAN A DOPTED BY THE B OARD OF D IRECTORS : J ULY 28, 2025 1. G ENERAL . (a) Plan Purpose. The Company, by means of the Plan, seeks to secure and retain the services of El
I Magene Bio, Inc. has announced the adoption of a 2025 equity inducement plan by its Board of Directors. The plan is designed to attract and retain eligible employees by providing them with incentives linked to the company's stock performance. The Board can grant nonstatutory stock options and restricted stock units under specific guidelines dictated by Nasdaq rules. The plan includes provisions on share reserves and eligibility, aiming to promote employee engagement and commitment to the company's success.
Read more →IMA▼ -7.1%on this newsshared move
Corporate Overview July 2025 Disclaimer This presentation contains "forward-looking statements" under the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. ImageneBio, Inc.'
ImageneBio, Inc. has outlined its forward-looking statements regarding the development of its lead program, IMG-007, aimed at treating atopic dermatitis (AD) and alopecia areata (AA). The company has reported promising initial results from clinical trials, showing rapid and sustained improvements in patient scores for AD. However, the presentation highlights significant risks, including the uncertainties involved in clinical trials and the overall financial health of the company. The completion of a merger in July 2025 is expected to enhance Imagene's strategic position in the biopharmaceutical industry.
Read more →IMAInmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million The combined company will operate under the name ImageneBio, Inc. and will begin trading on N
Inmagene Biopharmaceuticals has completed its merger with Ikena Oncology, forming a new entity named ImageneBio, Inc., which will begin trading on Nasdaq under the ticker symbol IMA on July 28, 2025. The merger is accompanied by a $75 million private placement aimed at advancing the clinical development of IMG-007, a monoclonal antibody targeting OX40 for treating immunological diseases. ImageneBio is set to continue its Phase 2b trial for IMG-007 in moderate-to-severe atopic dermatitis, with topline results expected in late 2026.
Read more →IMAIkena Oncology Announces Stockholder Approval of Merger with Inmagene Biopharmaceuticals Combined Company to Trade on Nasdaq Under Ticker IMA Ikena Announces 1-for-12 Reverse Stock Split of Ikena Common Stock BOSTON, MA
Ikena Oncology has announced that stockholders have approved the merger with Inmagene Biopharmaceuticals, enabling the combined company to list on Nasdaq under the ticker IMA. Additionally, a reverse stock split of 1-for-12 has been confirmed, reducing the total number of shares. The merger's completion and the new trading arrangements are expected to initiate around the end of July. Ikena is known for its development of therapies targeting cancer, while Inmagene has focused on therapeutics for immunological and inflammatory diseases.
Read more →IMAIkena Oncology Announces ISS and Glass Lewis Recommend Stockholders Vote FOR Proposed Merger with Inmagene Biopharmaceuticals BOSTON
Ikena Oncology has announced that Institutional Shareholder Services and Glass Lewis have recommended stockholders approve the proposed merger with Inmagene Biopharmaceuticals. This recommendation is crucial as Ikena's Annual Meeting is set for July 15, 2025, where stockholders will vote on this and other proposals. The merger aims to leverage Inmagene's lead candidate, IMG-007, which has shown promise in treating atopic dermatitis. The merger's approval could significantly impact Ikena's market position and growth potential in immunological and inflammatory diseases.
Read more →IMAInmagene Doses First Patient in the ADAPTIVE Phase 2b Trial of IMG-007, a Nondepleting Anti-OX40 mAb with an Extended Half-life, in Patients with Moderate-to-Severe Atopic Dermatitis The ADAPTIVE Phase 2b trial evaluates
Inmagene Biopharmaceuticals has announced the successful dosing of the first patient in its global Phase 2b trial (ADAPTIVE) for IMG-007, aimed at treating moderate-to-severe atopic dermatitis (AD). This trial will explore various dosing regimens with about 220 participants enrolled. The primary endpoint is the percentage change in the Eczema Area and Severity Index (EASI) score at Week 20. The anticipated topline results are expected in Q4 2026, which will inform future Phase 3 studies.
Read more →About ImageneBio, Inc.
Headquarters12526 HIGH BLUFF DRIVE, SAN DIEGO, CA, 92130
BIOPHARMAWATCH ELITE PLUS
Trade the next IMA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime